Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

NCT00309647 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
BIOLOGICAL: Influenza Monovalent Whole virus (H5N1)

Sponsor

GlaxoSmithKline